新冠肺炎全球大流行以來,對可能面臨藥物原料供應短缺,進而導致慢性病患所需服用的常規藥物短缺問題,Dr. Alexander和Dr. Qato提出以下幾個因應措施:1.建議政府列出普遍使用的常規藥物清單,確保這些藥物取得無虞;2.對這些常規藥物,應與藥廠協調訂出一套合理公平的分配措施;3.放寬現行取藥的管道,例如:可採郵購或宅配到府的管道;此外,私人保險業者應放寬理賠標準,尤其是對經濟弱勢的族群;此外,建議政府應做長遠考量規劃,在下次緊急事件來臨時,確保治療慢性疾病的常規藥物來源,供應和取得不會產生問題。

(財團法人國家衛生研究院 蔡慧如博士摘要整理)

The coronavirus disease 2019 (COVID-19) pandemic continues to rapidly evolve. Given the origins of COVID-19 in China, there were initial concerns regarding medication shortages due to the reliance of the US on overseas manufacturing of active pharmaceutical ingredients.1,2 Although no major disruptions in pharmaceutical access have occurred thus far, the future of the pandemic and its effect on the US drug supply remains far from certain.

Author:G. Caleb Alexander,Dima M. Qato, PharmD, et al.
原文連結:https://jamanetwork.com/journals/jama/fullarticle/2764562